11 September 2020
Sydney's iconic Sun-Herald City2Surf 2020 is on Sunday 18 October 2020, it’s the 50th anniversary and this year the event is virtual, so more people can join in!
Hand sanitiser, social distancing, isolation, working from home…It’s all part of our ’new normal’. For events, the ‘new normal’ means a virtual event. It’s the perfect excuse to get a few mates together, enjoy the day and run, jog or walk 14kms in your neighbourhood to your own beat.
How does the virtual event work?
- Once you've registered you’ll receive an email with a link to download the C2S app
- Anytime between 6am and 6pm* on Sunday 18 October 2020, just open the C2S app and push ‘Start’. You’ll be tracked as if you're doing the actual C2S course - no matter where you are. (*MIA recommend avoiding the middle of the day when the UV rating is higher.)
- When you hit 14kms, the tracking will stop automatically, and your result will be submitted
- Be part of history! All finishers will receive C2S 50 year ‘bling’ (medal) and an exclusive 2020 bandana.
You’re invited to be a Charity Superstar!
Giving back to charity is the beating heart of City2Surf. Melanoma Institute Australia has 20 Charity Superstar places available to our fundraisers. We invite you to become one of 20 MIA Charity Superstars for this year’s City2Surf.
As a Charity Superstar you’ll be part of an exclusive group helping Melanoma Institute Australia achieve our mission of zero deaths from melanoma this decade. You’ll receive the following benefits:
- We’ll cover your C2S entry fee
- You’ll receive a ‘Run over Melanoma’ singlet, MIA hat and SunSense sunscreen
- Be part of the MIA and make a real difference for people impacted by melanoma
- Be rewarded for achieving your fundraising target of $1000 (we’ll support you!)
To apply to become a C2S Charity Superstar please click on the link below:
Together we can run over melanoma!
Visit the City2Surf website for more information about participating in this iconic event.
#City2Surf #LetsRunSydney #RunOverMelanoma.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.